BML Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

BML Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$87.6K	Buy	+71,839	New	+$294K	0.05%	20

Other funds holding KPTI

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

BML Capital Management's KPTI Position: Q3 2026 in Review

BML Capital Management opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 71,839 shares worth $87.6K. The stake represents 0.05% of the portfolio and ranks #20 among its holdings.

39 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

BML Capital Management held 71,839 shares of Karyopharm Therapeutics worth $87.6K as of Q3 2026.
Karyopharm Therapeutics was a new BML Capital Management position in Q3 2026.
Karyopharm Therapeutics made up 0.05% of BML Capital Management's portfolio in Q3 2026, its #20 holding.
39 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on BML Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.